Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03924193 · ClinicalTrials.gov registry record · Phase 3
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
A Phase 3 study of Obesity and Binge-Eating Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT03924193 is a Phase 3 study of Obesity and Binge-Eating Disorder that has completed, run by Yale University. The registered enrollment target is 141 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03924193, a Phase 3 study of Obesity and Binge-Eating Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
Brief Summary: This study will compare the effectiveness of cognitive behavioral therapy (CBT), lisdexamfetamine (LDX), and the combination of CBT and LDX for the treatment of binge-eating disorder in patients with obesity. This is an acute treatment comparing CBT or LDX alone or in combination.
Conditions Studied
Interventions
- DRUG Lisdexamfetamine Dimesylate
- BEHAVIORAL Cognitive-Behavioral Therapy
- OTHER Combination LDX and Cognitive-Behavioral Therapy
Study Locations (1)
Connecticut
- Yale Department of Psychiatry - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03924193
The ClinicalTrials.gov registry entry for NCT03924193 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Lisdexamfetamine Dimesylate is the first listed.
NCT03924193 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03924193 about?
NCT03924193 is a clinical study titled "Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment". Brief Summary: This study will compare the effectiveness of cognitive behavioral therapy (CBT), lisdexamfetamine (LDX), and the combination of CBT and LDX for the treatment of binge-eating disorder in patients with obesity. This is an acute treatment comparing CBT or LDX alone or in combination.
What is the current status of trial NCT03924193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2019-03-25. Estimated completion is 2023-09-13.
What conditions does trial NCT03924193 study?
This clinical trial studies the following conditions: Obesity, Binge-Eating Disorder.
What interventions are being tested in trial NCT03924193?
The interventions under investigation include: Lisdexamfetamine Dimesylate (DRUG), Cognitive-Behavioral Therapy (BEHAVIORAL), Combination LDX and Cognitive-Behavioral Therapy (OTHER).
Who is sponsoring clinical trial NCT03924193?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03924193 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.